...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia and lymphoma >No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?
【24h】

No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?

机译：在体外，t（8; 21）急性髓细胞性白血病对胞嘧啶阿拉伯糖苷没有优先敏感性：治疗强度或高剂量Ara-C对反应是否至关重要？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Acute myeloid leukemia (AML) patients with core binding factor abnormalities [inv(16) or t(8;21)] have a relatively good prognosis, especially patients with inv(16) when treated with high-dose cytosine arabinoside (AraC) containing regimens, whereas in the case of t(8;21) evidences in favor of such regimen are contrasting. We previously demonstrated that blast cells from inv(16)-positive AML patients are characterized by an increased sensitivity to AraC with higher incorporation of 3H AraC into DNA and the increase of induced apoptosis in vitro. In the present study we tested the sensitivity of leukemic cells from 15 t(8;21)-positive AML patients to AraC and compared it with the results obtained from cells of 74 patients with inv(16), "intermediate" or unfavourable incorporation of 3H AraC into DNA in cells with t(8;21) was significantly lower than in cells with inv(16) (P = 0.02) or normal karyotype (P = 0.04). Interestingly, the incorporation of the drug into DNA in t(8;21) cells was similar to thosewith "unfavourable" karyotype. Furthermore, AraC induced apoptosis in t(8;21)-positive AML cells was not increased. These data suggest that the mechanism of response to chemotherapy for t(8;21)-positive cells is probably different then in AML cells with inv(16), underlining the possible importance for patients carrying the t(8;21) of repeated high-dose regimens and not necessarily of high-dose AraC based ones.
机译：具有核心结合因子异常[inv（16）或t（8; 21）]的急性髓样白血病（AML）患者的预后相对较好，尤其是当接受含大剂量胞嘧啶阿拉伯糖苷（AraC）的inv（16）患者时方案，而在t（8; 21）的情况下，支持这种方案的证据却是相反的。我们以前证明，来自inv（16）阳性AML患者的胚细胞的特征是对AraC的敏感性提高，其中3H AraC掺入DNA的比例更高，并且体外诱导的凋亡增加。在本研究中，我们测试了15例t（8; 21）阳性AML患者的白血病细胞对AraC的敏感性，并将其与74例inv（16），“中度”或不良掺入的患者的细胞结果进行了比较。 t（8; 21）细胞中3H AraC进入DNA的频率明显低于inv（16）（P = 0.02）或正常核型（P = 0.04）的细胞。有趣的是，将药物掺入t（8; 21）细胞中的DNA与具有“不利”核型的细胞相似。此外，AraC诱导t（8; 21）阳性AML细胞凋亡没有增加。这些数据表明，t（8; 21）阳性细胞对化疗的反应机制可能与inv（16）的AML细胞不同，这突显出对于携带反复高t（8; 21）的患者可能具有重要意义剂量方案，不一定是基于大剂量AraC的方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号